ZA200507192B - Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives - Google Patents

Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives

Info

Publication number
ZA200507192B
ZA200507192B ZA200507192A ZA200507192A ZA200507192B ZA 200507192 B ZA200507192 B ZA 200507192B ZA 200507192 A ZA200507192 A ZA 200507192A ZA 200507192 A ZA200507192 A ZA 200507192A ZA 200507192 B ZA200507192 B ZA 200507192B
Authority
ZA
South Africa
Prior art keywords
tetrahydropyrimido
pyrimidin
perfluoroalkyl
derivatives
substituted
Prior art date
Application number
ZA200507192A
Other languages
English (en)
Inventor
Lochead Alistair
Saady Mourad
Slowinski Franck
Yaiche Philippe
Original Assignee
Sanofi Aventis
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Mitsubishi Pharma Corp filed Critical Sanofi Aventis
Publication of ZA200507192B publication Critical patent/ZA200507192B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200507192A 2003-03-21 2004-03-19 Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives ZA200507192B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03290728A EP1460076A1 (en) 2003-03-21 2003-03-21 Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives

Publications (1)

Publication Number Publication Date
ZA200507192B true ZA200507192B (en) 2007-03-28

Family

ID=32799141

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200507192A ZA200507192B (en) 2003-03-21 2004-03-19 Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives

Country Status (25)

Country Link
US (2) US7217715B2 (enExample)
EP (2) EP1460076A1 (enExample)
JP (1) JP4572194B2 (enExample)
KR (1) KR101070075B1 (enExample)
CN (1) CN100368412C (enExample)
AR (1) AR053082A1 (enExample)
AT (1) ATE433977T1 (enExample)
AU (1) AU2004222105B2 (enExample)
BR (1) BRPI0408605A (enExample)
CA (1) CA2517774C (enExample)
CY (1) CY1109345T1 (enExample)
DE (1) DE602004021572D1 (enExample)
DK (1) DK1608653T3 (enExample)
EA (1) EA009198B1 (enExample)
ES (1) ES2328812T3 (enExample)
IL (1) IL170634A (enExample)
MX (1) MXPA05010112A (enExample)
NO (1) NO20054331L (enExample)
NZ (1) NZ542224A (enExample)
PL (1) PL1608653T3 (enExample)
PT (1) PT1608653E (enExample)
SI (1) SI1608653T1 (enExample)
TW (1) TWI322809B (enExample)
WO (1) WO2004083210A1 (enExample)
ZA (1) ZA200507192B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460076A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
JP4277826B2 (ja) 2005-06-23 2009-06-10 住友電気工業株式会社 窒化物結晶、窒化物結晶基板、エピ層付窒化物結晶基板、ならびに半導体デバイスおよびその製造方法
US9708735B2 (en) 2005-06-23 2017-07-18 Sumitomo Electric Industries, Ltd. Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same
US8771552B2 (en) 2005-06-23 2014-07-08 Sumitomo Electric Industries, Ltd. Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1939187A1 (en) * 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
EP2138494A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
EP2138495A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138485A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted N-Oxide pyrazine derivatives
EP2138488A1 (en) 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2138498A1 (en) 2008-06-26 2009-12-30 sanofi-aventis Substituted tricyclic derivatives against neurodegenerative diseases
EP2138492A1 (en) * 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidin-4-one derivatives
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
ES2487623T3 (es) 2009-07-02 2014-08-22 Sanofi Derivados de 6,7,8,9-tetrahidro-pirimido{1,2-a}pirimidin-4-ona, su preparación y su aplicación farmacéutica
PL2655375T3 (pl) 2010-12-23 2015-05-29 Sanofi Sa Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001270884A (ja) * 2000-03-23 2001-10-02 Mitsubishi-Tokyo Pharmaceuticals Inc ピリミドン誘導体
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
TR200402342T4 (tr) * 2000-09-01 2004-11-22 Mitsubishi Pharma Corporation 2-Pirindinil-6,7,8,9- Tetrahidropyrimido[1,2-A] Pirimidin-4-On ve 7-Pirindinil-1,3-Dihydoimidazo[1,2-A]Pirimidin-5(1H) on Türevleri
EP1184383A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
EP1460076A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives

Also Published As

Publication number Publication date
DE602004021572D1 (de) 2009-07-30
US7393853B2 (en) 2008-07-01
AR053082A1 (es) 2007-04-25
NO20054331L (no) 2005-12-21
CN100368412C (zh) 2008-02-13
NZ542224A (en) 2008-11-28
KR101070075B1 (ko) 2011-10-04
IL170634A (en) 2012-02-29
TWI322809B (en) 2010-04-01
EP1608653B1 (en) 2009-06-17
US7217715B2 (en) 2007-05-15
TW200505922A (en) 2005-02-16
AU2004222105B2 (en) 2010-03-04
CY1109345T1 (el) 2014-07-02
EA009198B1 (ru) 2007-12-28
KR20050111781A (ko) 2005-11-28
SI1608653T1 (sl) 2009-12-31
MXPA05010112A (es) 2006-05-17
EA200501311A1 (ru) 2006-04-28
JP4572194B2 (ja) 2010-10-27
HK1088893A1 (en) 2006-11-17
WO2004083210A1 (en) 2004-09-30
CA2517774A1 (en) 2004-09-30
NO20054331D0 (no) 2005-09-20
CN1784407A (zh) 2006-06-07
DK1608653T3 (da) 2009-10-05
PL1608653T3 (pl) 2009-12-31
EP1608653A1 (en) 2005-12-28
US20060035910A1 (en) 2006-02-16
EP1460076A1 (en) 2004-09-22
CA2517774C (en) 2011-10-18
BRPI0408605A (pt) 2006-03-07
PT1608653E (pt) 2009-09-07
JP2006520766A (ja) 2006-09-14
ES2328812T3 (es) 2009-11-18
ATE433977T1 (de) 2009-07-15
AU2004222105A1 (en) 2004-09-30
US20070191384A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
EP1653969A4 (en) PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
NO2017014I1 (no) 6-acetyl-8-cyclopentyl-5-metyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-on
TWI365189B (en) Novel pyrrolo[3,2-d]pyrimidin-4-one derivatives
PL1699795T3 (pl) Podstawione pochodne 8’-piry(mi)dynylo-dihydrospiro-[cykloalkiloamino]-pirymido[1,2-a]pirymidyn-6-onu
IL196021A0 (en) Pyrazolopyridine derivatives uses
IL159832A0 (en) 4-amino-6-phenyl-pyrrolo[2,3-d] pyrimidine derivatives
AU2003253532A1 (en) Substituted pyrrolopyridines
ZA200605901B (en) Pyrazolo [3,4-B] pyridine compounds, and their use as phosphodiesterase inhibitors
PL373223A1 (en) 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives
PL377227A1 (pl) Postawione pochodne heksahydropirazyno [1,2-a] pirymidyno-4,7-dionu, sposób ich wytwarzania i ich zastosowanie jako środków leczniczych
IL175813A0 (en) PYRIDO [2,3-d] PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS
IL163287A (en) HETEROARYL SUBSTITUTED 2 - PYRIDINYL AND 2 - PYRIMIDINYL - 6,7,8,9 - TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
AU2003255323A8 (en) Imidazo`1,2-a pyridines
SI1534707T1 (sl) Substituirani derivati 2,4-dihidro-pirolo(3,4-b)kinolin-9-ona, uporabni kot fosfodiesterazni inhibitorji
AU2003211993A1 (en) (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES
AU2003215676A1 (en) Pyrazolopyrimidines derivatives
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
ZA200600471B (en) 7-substituted 3-nitro-pyrazolo[1,5-A] pyrimidines
HK1084664A (en) Pyrazolo [1,5-a] pyrimidine derivatives
GB0214544D0 (en) 6-Crbamoylpyrimido[4,5-b]Indole derivatives
SI1549647T1 (sl) Substituirani C-imidazo(1,2-a)piridin-3-il-metilamini
HK1102440A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors